3 transcripts
URGN
Earnings call transcript
NASDAQ
2024 Q1
13 May 24
are actively advancing the development of next-generation formulations of UGN-102 and JELMYTO.
The investigational new drug application for UGN-103
URGN
Earnings call transcript
NASDAQ
2023 Q4
14 Mar 24
and nice data coming out of our registry and out of some investigator-initiated areas. So thanks. We'll keep you guys posted as we -- as things go along
URGN
Earnings call transcript
NASDAQ
2023 Q2
10 Aug 23
results from 2 Phase III clinical trials, investigating the use of UGN-102 to treat patients with low-grade intermediate risk non-muscle invasive bladder
- Prev
- 1
- Next